Glenmark receives tentative ANDA approval for Dronedarone Tablets, 400 mg

06 Jan 2016 Evaluate

Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for its Dronedarone Tablets, 400 mg, the generic version of Multaq Tablets, 400 mg of Sanofi-Aventis U.S., LLC. ‘Tentative approval’ means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections or exclusivities.

Glenmark is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for Dronedarone Tablets and expects to be eligible for 180 days of generic drug exclusivity upon final FDA approval. Glenmark remains involved in a patent litigation in the U.S. District Court for the District of Delaware, wherein Sanofi and Sanofi-Aventis U.S., LLC has asserted its patents. According to IMS Health sales data for the 12 month period ending November 2015, the Multaq market achieved annual sales of approximately $425.7 million.

Glenmark’s current portfolio consists of 104 products authorized for distribution in the U.S. marketplace and 62 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×